Webcast CME

Series Activities

Series Menu

Medical Dermatology Therapy Update




IL-23 Inhibitors and Other Emerging Psoriasis Treatments

Print this Content

Release Date:   July 3, 2018
Expiration Date:   July 3, 2020

Estimated Time of Completion:   30 minutes

Description

Medical Dermatology Therapy Update online series will provide a review of traditional therapeutics, as well as biologic and small-molecule therapies, as it applies to a range of important medical dermatologic conditions. In addition it includes an overview of the pathogenesis and diagnosis of various medical dermatologic diseases.

This webcast will discuss emerging treatments for psoriasis along with IL-23.

Learning Objectives

  1. Recognize elements of immunological pathways in psoriasis that differentiate different forms of biologic therapy
  2. Review the clinical characteristics that differentiate anti-IL-23 therapy from other treatment options in psoriasis
  3. Identify appropriate patients for treatment with anti-IL-23 therapy

Target Audience

These activities are directed to physicians and advanced practice clinicians in dermatology, immunology, oncology, rheumatology, internal medicine, and other health care professionals caring for patients with autoimmune, chronic inflammatory, and advanced malignant diseases.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director

Anthony P. Fernandez, MD, PhD
Director of Medical Dermatology
Department of Dermatology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH

Faculty

Kenneth B. Gordon, MD
Professor and Chair
Department of Dermatology
Medical College of Wisconsin
Milwaukee, WI


CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:


Anthony P. Fernandez, MD, PhD
  AbbVie Pharmaceuticals Consulting; Independent contractor (including contracted research); Teaching and Speaking
  Celgene Corporation Teaching and Speaking
  Mallinckrodt Inc. Independent contractor (including contracted research); Teaching and Speaking
  Roche Pharmaceuticals Principal Investigator for a Phase III Clinical Trial
 
Kenneth B. Gordon, MD
  Abbvie Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis Pharmaceuticals Consulting; Independent contractor (including contracted research)
  Amgen, Celgene Corporation, Dermira, Inc, GlaxoSmithKline, Sun Pharmaceutical Industries Ltd., UCB, Valeant Pharmaceuticals International Consulting
 


Acknowledgment

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:

Abbvie, Inc.
Genentech
Janssen Scientific Affairs, LLC
Lilly USA, LLC
Novartis Pharmaceuticals Corporation


The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Live activity from:

Abbvie, Inc.
Celgene Corporation
Genentech
Genzyme Corporation
Janssen Scientific Affairs, LLC
Lilly USA, LLC
Mallinckrodt, LLC
Novartis Pharmaceuticals Corporation
Pfizer
Valeant Pharmaceuticals North American, LLC

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education
and the Dermatology and Plastic Surgery Institute.